Molecular determinants of hERG channel block

Molecular Pharmacology

Volumn 69, Issue 5, 2006, Pages 1709-1716

  Kamiya, Kaichiro ^a   Niwa, Ryoko ^a   Mitcheson, John S ^b   Sanguinetti, Michael C ^c  

^a NAGOYA UNIVERSITY   (Japan)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; ALANINE; BEPRIDIL; DOFETILIDE; GLYCINE; IBUTILIDE; NIFEKALANT; PHENYLALANINE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; SERINE; SULFONE DERIVATIVE; THREONINE; TYROSINE; VALINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DEPOLARIZATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIVITY; FEMALE; MICROELECTRODE; MUTATION; NONHUMAN; OOCYTE; POROSITY; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS; VOLTAGE CLAMP; XENOPUS LAEVIS;

DNA PRIMERS; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; KINETICS; LONG QT SYNDROME; MUTAGENESIS, SITE-DIRECTED; PATCH-CLAMP TECHNIQUES; PHENETHYLAMINES; PIPERIDINES; POTASSIUM CHANNEL BLOCKERS; PYRIDINES; RECOMBINANT PROTEINS; SULFONAMIDES;

EID: 33645816995     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.020990     Document Type: Article

References (28)

1. Armstrong CM (1971) Interaction of tetraethylammonium ion derivatives with the potassium channels of giant axons. J Gen Physiol 58:413-437.
2. + channel blockers. J Med Chem 45:3844-3853.
3. + channels. J Pharmacol Sci 95:311-319.
4. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, and Keating MT (1995) A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80:795-803.
5. o. J Pharmacol Toxicol Methods 50:187-199.
6. + conduction and selectivity. Science 280:69-77.
7. Ekins S, Crumb WJ, Sarazan RD, Wikel JH, and Wrighton SA (2002) Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J Pharmacol Exp Ther 301:427-434.
8. Fernandez D, Ghanta A, Kauffman GW, and Sanguinetti MC (2004) Physicochemical features of the hERG channel drug binding site. J Biol Chem 279:10120-10127.
9. 3H]Dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. Eur J Pharmacol 430:147-148.
10. Lees-Miller JP, Duan Y, Teng GQ, and Duff HJ (2000) Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol Pharmacol 57:367-374.
11. Milnes JT, Crociani O, Arcangeli A, Hancox JC, and Witchel HJ (2003) Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol 139:887-898.
12. Mitcheson JS, Chen J, Lin M, Culberson C, and Sanguinetti MC (2000a) A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 97:12329-12333.
13. Mitcheson JS, Chen J, and Sanguinetti MC (2000b) Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J Gen Physiol 115:229-240.
14. Pearlstein RA, Vaz RJ, Kang J, Chen XL, Preobrazhenskaya M, Shchekotikhin AE, Korolev AM, Lysenkova LN, Miroshnikova OV, Hendrix J, et al. (2003) Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg Med Chem Lett 13:1829-1835.
15. Perry M, de Groot MJ, Helliwell R, Leishman D, Tristani-Firouzi M, Sanguinetti MC, and Mitcheson J (2004) Structural determinants of HERG channel block by clofilium and ibutilide. Mol Pharmacol 66:240-249.
16. Perry M, Stansfeld PJ, Leaney J, Wood C, de Groot MJ, Leishman D, Sutcliffe MJ, and Mitcheson JS (2006) Drug binding interactions in the inner cavity of HERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs. Mol Pharmacol 69:509-519.
17. + channel. J Mol Cell Cardiol 36:701-705.
18. + channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656. Biochem Biophys Res Commun 325:883-891.
19. Sanchez-Chapula JA, Ferrer T, Navarro-Polanco RA, and Sanguinetti MC (2003) Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. Mol Pharmacol 63:1051-1058.
20. + channel block. J Biol Chem 277:23587-23595.
21. + channels by halofantrine. Naunyn-Schmiedeberg's Arch Pharmacol 370:484-491.
22. Kr potassium channel. Cell 81:299-307.
23. + current: differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 96:195-215.
24. Sanguinetti MC and Xu QP (1999) Mutations of the S4-S5 linker alter activation properties of HERG potassium channels expressed in Xenopus oocytes. J Physiol 514:667-675.
25. Sarkar G and Sommer SS (1990) The "megaprimer" method of site-directed mutagenesis. Biotechniques 8:404-407.
26. + channel; open channel block by methanesulfonanilides. Circ Res 78:499-503.
27. Stuehmer W (1992) Electrophysiological recording from Xenopus oocytes. Methods Enzymol 207:319-339.
28. Witchel HJ, Dempsey CE, Sessions RB, Perry M, Milnes JT, Hancox JC, and Mitcheson JS (2004) The low potency, voltage-dependent HERG blocker propafenone - molecular determinants and drug trapping. Mol Pharmacol 66:1201-1212.